Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2015;18(4):242-7.
doi: 10.1159/000433518. Epub 2015 Jun 26.

Translational Genomics in Low- and Middle-Income Countries: Opportunities and Challenges

Affiliations

Translational Genomics in Low- and Middle-Income Countries: Opportunities and Challenges

Fasil Tekola-Ayele et al. Public Health Genomics. 2015.

Abstract

Translation of genomic discoveries into patient care is slowly becoming a reality in developed economies around the world. In contrast, low- and middle-income countries (LMIC) have participated minimally in genomic research for several reasons including the lack of coherent national policies, the limited number of well-trained genomic scientists, poor research infrastructure, and local economic and cultural challenges. Recent initiatives such as the Human Heredity and Health in Africa (H3Africa), the Qatar Genome Project, and the Mexico National Institute of Genomic Medicine (INMEGEN) that aim to address these problems through capacity building and empowerment of local researchers have sparked a paradigm shift. In this short communication, we describe experiences of small-scale medical genetics and translational genomic research programs in LMIC. The lessons drawn from these programs drive home the importance of addressing resource, policy, and sociocultural dynamics to realize the promise of precision medicine driven by genomic science globally. By echoing lessons from a bench-to-community translational genomic research, we advocate that large-scale genomic research projects can be successfully linked with health care programs. To harness the benefits of genomics-led health care, LMIC governments should begin to develop national genomics policies that will address human and technology capacity development within the context of their national economic and sociocultural uniqueness. These policies should encourage international collaboration and promote the link between the public health program and genomics researchers. Finally, we highlight the potential catalytic roles of the global community to foster translational genomics in LMIC.

PubMed Disclaimer

Figures

Figure 1
Figure 1. Factors for effective translation of genomics to health care practice in global settings
Integration of genomics research with clinical and public health care, and the cycle of bench-to-clinic-to-community in global settings is influenced by three key factors: local and global policy and governance (public health policy and ethical guidance), resource (infrastructure, funding, and technology), and socio-cultural factors.

References

    1. Manolio TA, Chisholm RL, Ozenberger B, Roden DM, Williams MS, Wilson R, Bick D, Bottinger EP, Brilliant MH, Eng C, et al. Implementing genomic medicine in the clinic: the future is here. Genetics in medicine : official journal of the American College of Medical Genetics. 2013;15:258–267. - PMC - PubMed
    1. Research capacity. Enabling the genomic revolution in Africa. Science. 2014;344:1346–1348. - PMC - PubMed
    1. Gurdasani D, Carstensen T, Tekola-Ayele F, Pagani L, Tachmazidou I, Hatzikotoulas K, Karthikeyan S, Iles L, Pollard MO, Choudhury A, et al. The African Genome Variation Project shapes medical genetics in Africa. Nature. 2015;517:327–332. - PMC - PubMed
    1. Moreno-Estrada A, Gignoux CR, Fernandez-Lopez JC, Zakharia F, Sikora M, Contreras AV, Acuna-Alonzo V, Sandoval K, Eng C, Romero-Hidalgo S, et al. Human genetics. The genetics of Mexico recapitulates Native American substructure and affects biomedical traits. Science. 2014;344:1280–1285. - PMC - PubMed
    1. McKinnell JA, Saag MS. Novel drug classes: entry inhibitors [enfuvirtide, chemokine (C-C motif) receptor 5 antagonists] Current opinion in HIV and AIDS. 2009;4:513–517. - PubMed

Publication types

MeSH terms

LinkOut - more resources